Catalyst Event
Pfizer Inc (PFE) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/30/2026, 12:00:00 AM
Pfizer announced positive Phase 3 TALAPRO-3 trial results on 2026-05-30 for Talzenna plus Xtandi; Medium importance estimated due to significant reduction in disease progression risk.
Korean Translation
화이자가 2026년 05월 30일 3상 TALAPRO-3 임상시험의 긍정적 결과를 발표하였으며, 유의미한 지표 개선으로 중간 수준의 중요도가 예상됨.
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM